Latest news with #CloverHealth
Yahoo
20 hours ago
- Business
- Yahoo
Why Is Clover Health (CLOV) Stock Soaring Today
What Happened? Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 9.5% in the afternoon session after the stock gained ground amid broader positive market sentiment ahead of a busy week for corporate earnings. U.S. stock futures pointed to a higher open for the markets, creating a positive backdrop for investors who were anticipating a full slate of earnings reports from major companies during the week. Notably, the earnings season got off to a strong start: More than 85% of the S&P 500 stocks that reported earnings exceeded expectations, according to FactSet data. This robust performance fueled positive sentiment, suggesting that corporate profitability remained resilient despite ongoing economic uncertainties. In the absence of any fresh catalysts from the healthcare technology company, its shares appeared to be lifted by the general market updraft. Is now the time to buy Clover Health? Access our full analysis report here, it's free. What Is The Market Telling Us Clover Health's shares are extremely volatile and have had 44 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 10 days ago when the stock dropped 4.8% on the news that a filing revealed that the company's CEO, Wai Conrad, sold a portion of his holdings. According to a regulatory filing on July 11, 2025, CEO Wai Conrad sold 15,203 shares of Class A Common Stock on July 8 for a total of approximately $49,561. The transactions were made at prices ranging from $3.25 to $3.27 per share. While the sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which allows insiders to sell a predetermined number of shares at a predetermined time, the news can still create unease among investors. Insider selling, even when planned, is often scrutinized by the market for any signals about a company's future prospects, contributing to negative pressure on the stock price. Clover Health is up 1.4% since the beginning of the year, but at $3.18 per share, it is still trading 34.1% below its 52-week high of $4.82 from January 2025. Investors who bought $1,000 worth of Clover Health's shares 5 years ago would now be looking at an investment worth $285.27. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Clover Health to Participate in Upcoming Canaccord Genuity 45th Annual Growth Conference
WILMINGTON, Del., July 21, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ('Clover,' 'Clover Health' or the 'Company'), today announced that its Chief Financial Officer, Peter Kuipers, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 11:00 a.m. Eastern Time. A live webcast and replay of the presentation will be accessible from Clover Health's investor relations website at About Clover Health:Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology's impact on Medication Adherence and Congestive Heart Failure, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease. Investor Relations:Ryan Schmidtinvestors@ Press Inquiries:press@ in to access your portfolio
Yahoo
12-07-2025
- Business
- Yahoo
Why Clover Health (CLOV) Shares Are Trading Lower Today
Shares of health insurance company Clover Health (NASDAQ:CLOV) fell 4.8% in the afternoon session after a filing revealed that the company's CEO, Wai Conrad, sold a portion of his holdings. According to a regulatory filing on July 11, 2025, CEO Wai Conrad sold 15,203 shares of Class A Common Stock on July 8 for a total of approximately $49,561. The transactions were made at prices ranging from $3.25 to $3.27 per share. While the sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which allows insiders to sell a predetermined number of shares at a predetermined time, the news can still create unease among investors. Insider selling, even when planned, is often scrutinized by the market for any signals about a company's future prospects, contributing to negative pressure on the stock price. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Clover Health? Access our full analysis report here, it's free. Clover Health's shares are extremely volatile and have had 45 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Clover Health is down 7.2% since the beginning of the year, and at $2.91 per share, it is trading 39.7% below its 52-week high of $4.82 from January 2025. Investors who bought $1,000 worth of Clover Health's shares 5 years ago would now be looking at an investment worth $261.71. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-07-2025
- Business
- Yahoo
Craig-Hallum Reiterates a Buy Rating on Clover Health Investments (CLOV), Sets a $6 PT
Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the 13 Stocks Under $5 With High Upside Potential. In a report released on May 7, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Clover Health Investments, Corp. (NASDAQ:CLOV) with a price target of $6.00. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company reported notable fiscal Q1 2025 results that support this optimistic outlook, with Medicare Advantage membership for the quarter reaching 103,418, representing a 30% year-over-year increase. Total revenue for fiscal Q1 2025 rose 33% year-over-year to $462 million, while adjusted EBITDA reached $26 million, reflecting a significant 279% year-over-year rise. Adjusted net income also grew 322% year-over-year to $25 million. In addition, Clover Health Investments, Corp. (NASDAQ:CLOV) reported a GAAP net loss of $1 million, compared to $19 million a year ago, suggesting a considerable improvement in its operations. Clover Health Investments, Corp. (NASDAQ:CLOV) is a physician enablement technology company that offers Medicare Advantage plans in the United States. It offers PPO and HMO Medicare Advantage plans in several US states. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio


Time Business News
06-07-2025
- Business
- Time Business News
Speculation Mounts Around Possible Clover Health
July 5, 2025 — New York — Talk of a potential partnership between Clover Health's AI division, Counterpart Health, and insurance giant Humana has gained traction after a string of digital breadcrumbs and recent corporate remarks ignited speculation throughout the healthcare and investment communities. While neither company has made a formal announcement, the circumstantial evidence has grown too aligned to ignore, hinting that Humana may be preparing to deploy Clover's AI platform across its vast Medicare Advantage operations. If true, the move could be a game-changer for both companies: a potential multi-billion-dollar opportunity for recently struggling Humana, and a defining moment in Clover Health's reinvention from insurance underdog to healthcare tech disruptor. The speculation began after Humana's June 16 investor meeting, during which executives outlined the company's path forward amid growing challenges. Humana has recently been under significant pressure due to declining Medicare Advantage Star Ratings, rising medical costs, and an increasingly complex regulatory environment. To address these headwinds, the company presented a long-term strategy focused on operational efficiency, automation, and simplification. Humana stated it would 'leverage outsourcing and technology to simplify and automate processes… while driving efficiencies'. What made the presentation even more notable was the timeline Humana laid out. The company projected a gradual improvement in cost efficiency – starting with baseline progress in 2026, and a full impact by 2028. That timeline is nearly identical to the three-year cost savings arc marketed by Counterpart Health, which claims its AI can reduce a payer's Medical Cost Ratio by 7% in year two and up to 15% by year three. While Humana did not mention specific partners, the language prompted the beginning of the speculation. The rumor mill kicked into high gear this week when a publicly available subdomain scan of Counterpart Health's website revealed a curious pattern. Alongside previously announced partners like Duke Connected Care, The Iowa Clinic, and Southern Illinois Healthcare, a number of new subdomains appeared bearing the Humana name. These backend URLs indicate that technical infrastructure might be under development to support a potential relationship between Counterpart and Humana. Notably, the same pattern of subdomains was observed prior to official announcements for Duke, Iowa Clinic, and Southern Illinois Healthcare, all of which later confirmed deals with Counterpart Health. While these web addresses alone don't confirm a deal, their presence strongly suggests that backend systems and integrations are potentially being developed in anticipation of one. Clover Health has touted its Counterpart Assistant platform as a game-changing clinical AI tool that can reduce a payer's Medical Cost Ratio by up to 15%. For context, Clover Health itself posted an MCR of 75.1% in 2024, one of the most efficient in the industry. Meanwhile, Humana has struggled with an increasing MCR due to a variety of headwinds. If Humana were to achieve even a fraction of the cost savings that Clover Health claims are possible, the financial impact could be enormous for the company – potentially saving billions annually. For Clover Health, such a partnership would represent a dramatic turning point. The company, which went public via SPAC in 2021, has spent years battling poor investor sentiment, regulatory scrutiny, and heavy skepticism over its long-term viability. Once seen as just another Medicare Advantage insurer, Clover has been actively repositioning itself around its AI platform, Counterpart Assistant – a tool designed to centralize patient data, assist physicians with real-time clinical insights, and reduce avoidable medical costs. The company attributes its own low MCR of 75.1% to this technology and has begun licensing it to external payers and provider groups under its Counterpart Health brand. A deal with Humana – one of the largest Medicare Advantage organizations in the country – would give Clover Health a level of validation it has never experienced. It would instantly elevate the perception of the company from a traditional insurer to a high-margin, health-AI disrupting SaaS. Investors would no longer value Clover based on insurance metrics, but rather on recurring software revenue, gross margins, and enterprise tech multiples. Although neither Humana nor Clover has commented publicly, and no regulatory filings have confirmed a formal agreement, the emerging pattern is increasingly difficult to ignore: a shared strategic direction, an almost identical cost-cutting timeline, and Humana's digital infrastructure woven into Counterpart Health's operations. If the partnership is ultimately validated, it could mark a major milestone for AI in healthcare – and potentially the long-awaited inflection point in the turnaround journeys of both Clover Health and Humana. TIME BUSINESS NEWS